Author

Raju Esanakarra

Institution: Biological E (India)

Observed institution: Biological E (India)

ORCID: 0009-0008-2262-5454

Observed ORCID: 0009-0008-2262-5454

OpenAlex ID: A5117667859

Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine (BE-PCV14) administered in a 3p + 1 schedule to healthy Indian infants and toddlers: a prospective, multicenter, active-controlled phase IV trial

2026 · Subhash Thuluva, Subbareddy Gunneri, et al. · BMC Infectious Diseases · 1

Immunogenicity and Safety of Biological E’s Monovalent rDNA Hepatitis B Vaccine (BEVAC®) in Neonates and Infants: A Multicentre, Randomized, Phase IV Non-Inferiority Trial

2026 · Subhash Thuluva, Subbareddy Gunneri, et al. · Viruses

A multi-centre, single arm, Phase 3 study to assess the safety and reactogenicity of biological Es Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine in ≥6 months old infants to ≤45 years old adults.

2025 · Subhash Thuluva, Ramesh V. Matur, et al. · Vaccine X

Works count: 3

Citation count: 1

H-index: 1

I10-index: